Clinical Trials Browser

Phase 2 × Neoplasms, Plasma Cell × Dexamethasone × Clear all

NCT03500445 2026-04-13

Daratumumab, Carfilzomib, Lenalidomide and Low Dose Dexamethasone (DKRd) in Newly Diagnosed, Multiple Myeloma

Phase 2 Active not recruiting

Multiple Myeloma, Neoplasms, Plasma Cell

NCT04151667 2026-03-11

Daratumumab Based Response Adapted Therapy for Older Adults With Newly Diagnosed Multiple Myeloma

Phase 2 Active not recruiting

33 enrolled 11 charts

Multiple Myeloma, Neoplasms, Plasma Cell

NCT03314636 2025-08-08

CONPET

Phase 2 Active not recruiting

Neoplasms, Plasma Cell

NCT02899052 2025-08-05

Study of Venetoclax in Combination With Carfilzomib and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma (MM)

Phase 2 Active not recruiting

Multiple Myeloma, Recurrence, Neoplasms, Plasma Cell

NCT04052880 2025-07-20

Study of SubQ Dara With Dose-Attenuated Bortezomib, Lenalidomide, Dexamethasone in Elderly NDMM

Phase 2 Active not recruiting

Multiple Myeloma, Neoplasms, Plasma Cell

NCT00871013 2025-07-01

Trial for Patients Not Qualifying for TT4 and TT5 Protocols Because of Prior Therapy

Phase 2 Active not recruiting

Neoplasms, Plasma Cell

NCT04891809 2025-04-10

Isatuximab in Combination With Rd Compared to Rd in Elderly Patients (Aged ≥70 Years) With NDMM

Phase 2 Active not recruiting

Neoplasms, Plasma Cell

NCT04782687 2025-01-16

Study of Selinexor Plus DRd for Newly Diagnosed Multiple Myeloma

Phase 2 Active not recruiting

Multiple Myeloma, Neoplasms, Neoplasms, Plasma Cell

NCT00482261 2024-11-08

A Study of Low Dose Lenalidomide and Dexamethasone in Relapsed/Refractory Myeloma in Patients at High Risk for Myelosuppression

Phase 2 Completed

Multiple Myeloma, Recurrence, Neoplasms, Plasma Cell

NCT05248633 2024-06-05

Chemotherapy Combined With Radiotherapy Versus Radiotherapy Alone for Solitary Plasmacytoma

Phase 2 Recruiting

Neoplasms, Plasma Cell

NCT03289299 2023-12-12

ASCENT

Phase 2 Active not recruiting

Smoldering Multiple Myeloma, Neoplasms, Plasma Cell

NCT04843579 2023-10-25

ClaSPd

Phase 2 Terminated

4 enrolled 9 charts

Multiple Myeloma, Neoplasms, Plasma Cell

NCT00305812 2023-08-04

Lenalidomide and Melphalan in Treating Patients With Previously Untreated Multiple Myeloma

Phase 2 Completed

Multiple Myeloma, Neoplasms, Plasma Cell

NCT03695744 2023-07-10

Daratumumab in Combination With Bortezomib and Dexamethasone in Newly Diagnosed Transplant Ineligible Multiple Myeloma

Phase 2 Unknown

Multiple Myeloma, Neoplasms, Plasma Cell

NCT03641456 2023-06-18

VRD as Induction Followed by VR Maintenance in Patients With Newly Diagnosed High Risk Multiple Myeloma

Phase 2 Unknown

Neoplasms, Plasma Cell

NCT00054158 2022-10-03

Combination Chemotherapy and Thalidomide in Treating Patients With Stage I, Stage II, or Stage III Multiple Myeloma

Phase 2 Completed

Multiple Myeloma, Neoplasms, Plasma Cell

NCT05147493 2022-03-29

A Phase 2 Study of Isatuximab in Combination With Bortezomib, Cyclophosphamide and Dexamethasone Followed by Isatuximab and Lenalidomide Maintenance in Newly Diagnosed Patients With Multiple Myeloma and Severe Renal Impairment

Phase 2 Unknown

Blood Protein Disorders, Hematologic Diseases, Multiple Myeloma, Neoplasms, Neoplasms by Histologic Type, Paraproteinemias, Renal Insufficiency, Neoplasms, Plasma Cell

NCT05298683 2022-03-28

A Phase 2 Study of Isatuximab in Combination With Pomalidomide and Dexamethasone in MM Patients Who Received One Prior Line of Therapy Containing Lenalidomide and a Proteasome Inhibitor

Phase 2 Unknown

Blood Protein Disorders, Hematologic Diseases, Multiple Myeloma, Neoplasms, Neoplasms by Histologic Type, Paraproteinemias, Renal Insufficiency, Neoplasms, Plasma Cell

NCT02424851 2022-01-27

OPTIMAL

Phase 2 Completed

31 enrolled 13 charts

Multiple Myeloma, Renal Insufficiency, Chronic, Renal Insufficiency, Neoplasms, Plasma Cell

NCT04065789 2022-01-27

KyDaR

Phase 2 Completed

Multiple Myeloma, Neoplasms, Plasma Cell

NCT00792142 2021-08-19

Bortezomib, Thalidomide, and Dexamethasone After Melphalan and Stem Cell Transplant in Treating Patients With Stage I-III Multiple Myeloma

Phase 2 Completed

45 enrolled 8 charts

Multiple Myeloma, Neurotoxicity Syndromes, Neoplasms, Plasma Cell

NCT00538733 2021-05-24

T-BiRD

Phase 2 Completed

26 enrolled 16 charts

Multiple Myeloma, Neoplasms, Plasma Cell

NCT00017069 2020-10-05

Arsenic Trioxide and Dexamethasone in Treating Patients With Recurrent or Refractory Stage II or Stage III Multiple Myeloma

Phase 2 Terminated

Multiple Myeloma, Neoplasms, Plasma Cell

NCT01237951 2020-05-05

High-Dose Gemcitabine, Busulfan and Melphalan With Hematopoietic-Cell Support for Patients With Poor-Risk Myeloma

Phase 2 Completed

75 enrolled 11 charts

Neoplasms, Plasma Cell

NCT00772915 2020-01-18

Lenalidomide With or Without Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma

Phase 2 Completed

39 enrolled 13 charts

Multiple Myeloma, Neoplasms, Plasma Cell

NCT01647165 2019-12-12

Phase II Study of Subcutaneous (SC) Bortezomib, Lenalidomide and Dexamethasone for Relapsed and/or Refractory Multiple Myeloma; Followed by SC Bortezomib Maintenance

Phase 2 Withdrawn

Multiple Myeloma, Neoplasms, Plasma Cell

NCT00003399 2019-10-17

Peripheral Stem Cell Transplantation Plus Combination Chemotherapy in Treating Patients With Multiple Myeloma

Phase 2 Completed

Multiple Myeloma, Neoplasms, Plasma Cell

NCT00003401 2019-10-17

Peripheral Stem Cell Transplantation Plus Combination Chemotherapy in Treating Patients With Multiple Myeloma

Phase 2 Completed

Multiple Myeloma, Neoplasms, Plasma Cell

NCT00049374 2019-10-17

Oblimersen, Thalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma

Phase 2 Completed

Multiple Myeloma, Neoplasms, Plasma Cell

NCT02188537 2019-06-26

Nelfinavir as Bortezomib-sensitizing Drug in Patients With Proteasome Inhibitor-nonresponsive Myeloma

Phase 2 Completed

Neoplasms, Plasma Cell

NCT03143036 2018-06-07

Daratumumab, Thalidomide and Dexamethasone in Relapse and/or Refractory Myeloma

Phase 2 Unknown

Recurrence, Neoplasms, Plasma Cell

NCT00538824 2018-06-06

DexTR

Phase 2 Terminated

5 enrolled 8 charts

Multiple Myeloma, Recurrence, Neoplasms, Plasma Cell

NCT00558896 2018-04-18

CC-4047 and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma or Amyloidosis

Phase 2 Completed

378 enrolled 13 charts

Multiple Myeloma, Neoplasms, Plasma Cell

NCT00005987 2017-11-29

Filgrastim Compared With Sargramostim Plus Chemotherapy, Peripheral Stem Cell Transplantation, and Interferon Alfa in Treating Patients With Multiple Myeloma

Phase 2 Terminated

Multiple Myeloma, Neoplasms, Plasma Cell

NCT01816620 2017-04-25

Study to Evaluate Lenalidomide Plus Dexamethasone in Patients With Newly Diagnosed POEMS Syndrome

Phase 2 Completed

POEMS Syndrome, Neoplasms, Plasma Cell

NCT00458822 2016-08-10

Melphalan and Autologous Stem Cell Transplant Followed By Bortezomib and Dexamethasone in Treating Patients With Previously Untreated Systemic Amyloidosis

Phase 2 Completed

40 enrolled 5 charts

Immunoglobulin Light-chain Amyloidosis, Multiple Myeloma, Neoplasms, Plasma Cell

NCT01501370 2016-05-10

ZLd_Ld

Phase 2 Withdrawn

Multiple Myeloma, Neoplasms, Plasma Cell

NCT00458705 2016-01-22

Bortezomib, Doxorubicin Hydrochloride Liposome, and Dexamethasone Followed by Thalidomide and Dexamethasone With or Without Bortezomib in Treating Patients With Multiple Myeloma

Phase 2 Completed

45 enrolled 6 charts

Multiple Myeloma, Neoplasms, Plasma Cell

NCT00814541 2014-12-31

PAD. ICORG 05-01, V11

Phase 2 Completed

Multiple Myeloma, Neoplasms, Plasma Cell

NCT02114502 2014-07-11

Carfilzomib/SAHA Combined With High-Dose Gemcitabine/Busulfan/Melphalan With Autologous Stem Cell Transplant in Myeloma

Phase 2 Withdrawn

Multiple Myeloma, Recurrence, Neoplasms, Plasma Cell

NCT00402181 2014-05-14

An Efficacy and Safety Study of Siltuximab in Participants With Relapsed or Refractory Multiple Myeloma

Phase 2 Completed

Multiple Myeloma, Neoplasms, Plasma Cell

NCT00389701 2014-01-10

Bortezomib and Dexamethasone in Treating Patients With Multiple Myeloma That Has Relapsed or Has Not Responded to Treatment

Phase 2 Unknown

Multiple Myeloma, Neoplasms, Plasma Cell

NCT02027220 2014-01-06

Combination of G-CSF, Bortezomib, Cyclophosphamide and Dexamethasone in Patients With Multiple Myeloma

Phase 2 Unknown

Neoplasms, Plasma Cell

NCT00742404 2013-12-18

Doxorubicin Hydrochloride Liposome, Bortezomib, and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma

Phase 2 Unknown

Multiple Myeloma, Neoplasms, Plasma Cell

NCT00003493 2013-07-18

Combination Chemotherapy in Treating Patients With Multiple Myeloma

Phase 2 Completed

Multiple Myeloma, Neoplasms, Plasma Cell

NCT00021359 2013-07-10

Isotretinoin Plus Dexamethasone in Treating Patients With Multiple Myeloma

Phase 2 Completed

Multiple Myeloma, Neoplasms, Plasma Cell

NCT00112879 2013-07-10

Arsenic Trioxide, Ascorbic Acid, Dexamethasone, and Thalidomide in Treating Patients With Multiple Myeloma

Phase 2 Withdrawn

Multiple Myeloma, Neoplasms, Plasma Cell

NCT00003007 2013-06-26

Interferon Alfa Following Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Stage III or Stage IV Multiple Myeloma

Phase 2 Completed

Multiple Myeloma, Neoplasms, Plasma Cell

NCT00564889 2013-05-14

Lenalidomide, Cyclophosphamide, and Dexamethasone in Treating Patients With Primary Systemic Amyloidosis

Phase 2 Completed

35 enrolled 11 charts

Immunoglobulin Light-chain Amyloidosis, Multiple Myeloma, Neoplasms, Plasma Cell

NCT00008242 2013-03-07

Thalidomide, Doxorubicin, and Dexamethasone in Treating Patients With Untreated Stage II or Stage III Multiple Myeloma

Phase 2 Completed

Multiple Myeloma, Neoplasms, Plasma Cell